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Abstract
Background: Prior studies suggested that vancomycin may be inferior to β-lactams for the empiric treatment of
methicillin-susceptible S. aureus (MSSA) bacteremia. We assessed whether empiric therapy with β-lactams compared
to vancomycin was associated with differences in clinical outcomes in patients with MSSA bacteremia.
Methods: We conducted a retrospective cohort study of adult inpatients with their first episode of MSSA bacteremia
at two tertiary care hospitals in Vancouver, Canada, between 2007 and 2014. Exposure was either empiric β-lactam or
vancomycin therapy. All patients received definitive treatment with cloxacillin or cefazolin. The primary outcome was
28-day mortality. Secondary outcomes were 90-day mortality, recurrent infection at 6 months, duration of bacteremia
and hospital length-of-stay. Outcomes were adjusted using multivariable logistic regression.
Results: Of 814 patients identified, 400 met inclusion criteria (β-lactam = 200, vancomycin = 200). Overall 28-day
mortality was 8.5 % (n=34). There were more cases of infective endocarditis in the β-lactam than in the vancomycin
group [45 (22.5 %) vs 23 (11.5 %), p < 0.01]. Adjusted mortality at 28 days was similar between the two groups (OR: 1.14;
95 % CI: 0.49–2.64). No differences in secondary outcomes were observed. Transition to cloxacillin or cefazolin occurred
within a median of 67.8 h in the vancomycin group.
Conclusions: Empiric therapy with β-lactams was not associated with differences in all-cause mortality, recurrent
infection, microbiological cure or hospital length-of-stay compared to vancomycin. Vancomycin monotherapy
may be appropriate for the empiric treatment of MSSA bacteremia if definitive therapy with cloxacillin or
cefazolin can be initiated within 3 days.
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Background
Staphylococcus aureus is the leading cause of bacteremia
and carries a mortality of 20–30 % in the 21st century
[1, 2]. Empiric vancomycin is commonly prescribed for
patients with S. aureus bacteremia (SAB) to cover
methicillin-resistant S. aureus (MRSA) as up to 50–60 %
of bloodstream isolates are methicillin-resistant at some
centres [3–8]. However, vancomycin is inferior to semi-
synthetic anti-Staphylococcal penicillins (e.g., cloxacillin)
and first generation cephalosporins (e.g., cefazolin) for
the definitive treatment of methicillin-susceptible S.
aureus (MSSA) bacteremia [9–11]. Cloxacillin and cefa-
zolin are considered the optimal agents against MSSA
and both are equally efficacious in treating MSSA
bacteremia [10]. Vancomycin is associated with higher
rates of infection-related mortality, re-infection and bacte-
riologic failure compared to cloxacillin or cefazolin in the
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definitive treatment of MSSA bacteremia [9, 12–15].
Whether vancomycin is inferior to β-lactams for em-
piric therapy remains to be fully elucidated. Early stud-
ies suggested that empiric vancomycin was associated
with worse outcomes compared to empiric β-lactam
therapy [3, 16, 17], but more recent data did not dem-
onstrate any differences in outcomes [15]. Although
controversial, some experts recommend the addition of
a β-lactam agent to vancomycin during empiric treat-
ment to ensure optimal coverage for MSSA for patients
at the highest risk of morbidity and mortality from SAB
[18]. Major limitations of previous studies were failure
to control for the definitive therapy prescribed when
comparing empiric regimens and neglecting to specify
the empiric β-lactams used [3, 15–17]. We assessed if
empiric β-lactam compared to vancomycin was associated
with differences in survival, recurrent infection and micro-
biological cure in patients with MSSA bacteremia who re-
ceived definitive therapy with cloxacillin or cefazolin.
Methods
Patients
We performed a retrospective cohort study of adult in-
patients diagnosed with their first episode of MSSA
bacteremia at two tertiary care hospitals in Vancouver,
Canada, between January 2007 and December 2014, in-
clusive. Consecutive patients were included if they had
MSSA bacteremia and either cloxacillin or cefazolin was
prescribed for definitive therapy (penicillin was an ac-
ceptable alternative if the isolate was proven to be sus-
ceptible). Patients were excluded if there was missing
data for 28-day mortality, no empiric therapy was
administered, death occurred within 24 h following
diagnosis of bacteremia, or polymicrobial bacteremia.
Patients were stratified based on empiric treatment
with β-lactams or vancomycin. The β-lactam group
received one or more of cloxacillin, cefazolin, β-lactam/
β-lactamase inhibitor combination, a third generation
cephalosporin or a carbapenem, with or without vanco-
mycin. In both groups, other antimicrobials may have
been prescribed during empiric and definitive therapy.
Definitions
Bacteremia was defined as the isolation of MSSA from one
or more blood culture bottles. Bacteremia identified within
72 h of hospital admission was considered community-
onset, while bacteremia diagnosed after more than 72 h of
hospital admission was deemed hospital-onset. Immuno-
compromised state was present if any of the following
were described: neutropenia (≤ 1.5 × 109/L), congenital im-
mune deficiencies, or use of immunosuppressants (TNF-α
inhibitors, prednisone ≥ 10 mg/day or its equivalent,
cancer chemotherapy, methotrexate, cyclophosphamide,
mycophenolate mofetil, calcineurin inhibitors, mTOR
inhibitors, azathioprine and any other drug generally
considered to significantly weaken the immune system).
Definite infective endocarditis was diagnosed using the
modified Duke criteria [19]. The source of bacteremia
was either stated explicitly or inferred as the most likely
source based on available clinical data and microbio-
logical results. Metastatic complications included infec-
tions that occurred distant from the presumed primary
source such as septic emboli, mycotic aneurysms,
osteoarticular infections, and distant abscesses. Surgical
source control included only procedures performed in
the operating theatre. Empiric therapy began with the
first dose of empiric antibiotics and ended with the
start of definitive therapy. Definitive therapy began
when antimicrobial susceptibilities were known and
one of the following treatments was prescribed: 1) clox-
acillin or cefazolin 2) discontinuation of other empiric
antibiotics for patients already on cloxacillin or cefazo-
lin empirically, or 3) continuation of empiric cloxacillin
or cefazolin. Definitive therapy ended when cloxacillin
or cefazolin was stopped. Time to receipt of antibiotics
was measured from the time of obtaining the first posi-
tive blood culture to the time of the first dose of anti-
biotic. If a patient was already on antibiotics at the time
of the first positive blood culture, the time to receipt of
antibiotics was zero. We calculated the hours of em-
piric β-lactam exposure based on start and stop dates,
start and stop times, and dosing frequency.
Outcomes
Our primary outcome was 28-day all-cause in-hospital
mortality. Secondary outcomes were 90-day all-cause in-
hospital mortality, recurrent infection at 6 months, dur-
ation of bacteremia and hospital length-of-stay (LOS).
Time to mortality was measured from the date of the
first positive blood culture to the date of death. Recur-
rent infection occurred when MSSA bacteremia was di-
agnosed again following completion of a treatment
course for the previous episode of MSSA bacteremia.
Duration of bacteremia was the time difference be-
tween the first positive blood culture and the first nega-
tive blood culture. Patients without follow-up blood
cultures were excluded from the analysis for duration
of bacteremia. Hospital LOS was measured from the
date of admission to the date of discharge.
Data extraction
Patients with MSSA bacteremia were extracted from the
medical microbiology laboratory information systems
and medical records were reviewed. A single reviewer
collected data on patient demographics and comorbidi-
ties, blood culture results and antimicrobial therapy
from electronic and paper databases.
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Statistical analysis
Our predicted mortality difference between the β-lactam
and vancomycin group was 15 % based on a previous
study [17]. We estimated a sample size of 200 for each
group to capture a 15 % difference in mortality with
80 % power at a two-tailed alpha level of 0.05. Baseline
categorical variables were described as counts and per-
centages, and differences between groups were assessed
with chi-square or Fisher’s exact tests. Continuous vari-
ables were presented as means and standard deviations,
or medians and interquartile range. Differences between
groups were assessed using parametric t-tests or non-
parametric Mann–Whitney-U tests, as appropriate. Lo-
gistic regression methods were used to model the odds
ratio of death and recurrent infection in the β-lactam
compared to vancomycin group. Linear regression
model was conducted for hospital LOS and duration of
bacteremia. The two outcomes were log-transformed in
the analysis to improve normality of the distribution of
residuals. All models were adjusted for pre-specified
confounding variables including age, sex, age-adjusted
Charlson-comorbidity index [20], Pitt bacteremia score,
infectious diseases consultation, infective endocarditis
and time to receipt of empiric antibiotics. These factors
have been shown to affect mortality in patients with
SAB [1]. The duration of bacteremia was further ad-
justed for surgical source control. All analyses were
performed using the SAS 9.4 software.
Results
We identified 814 patients with MSSA bacteremia be-
tween January 2007 and December 2014, inclusive (Fig. 1).
We excluded 414 patients primarily because 60.4 % did
not receive cloxacillin or cefazolin for definitive therapy.
These patients either remained on broad-spectrum anti-
microbials or received vancomycin for definitive therapy
due to suspected or confirmed penicillin allergy. Another
22.9 % were not started on empiric therapy. Our cohort
consisted of 64.5 % males and 82.8 % of patients had
community-onset bacteremia (Table 1). Infectious diseases
consultation was obtained in most cases (70.5 %), but was
higher in the β-lactam than in the vancomycin group
(75 % vs 66 %, p=0.05). The most common sources of
bacteremia were unknown (26 %), injection drug use
(21.8 %), peripheral or central venous catheters (15.3 %),
and skin and soft tissue infections (15 %). Infective endo-
carditis was diagnosed more frequently in the β-lactam
than in the vancomycin group (22.5 % vs 11.5 %, p < 0.01).
The prevalence of infective endocarditis was 17.0 %. The
β-lactam group experienced more metastatic complica-
tions (36.5 % vs 26.5 %, p=0.03) and underwent surgical
source control more frequently (21.5 % vs 13 %, p=0.02)
compared to the vancomycin group.
The most common empiric antimicrobials prescribed
in the β-lactam group were vancomycin (76.5 %), cloxa-
cillin or cefazolin (69 %), 3rd generation cephalosporins
(40 %) and piperacillin-tazobactam (34.5 %). The use of
multiple β-lactam antibiotics reflects changes made dur-
ing empiric therapy. Among the subgroup of patients
who received combination therapy with β-lactam plus
vancomycin (153/200), cloxacillin or cefazolin (62.1 %),
3rd generation cephalosporins (47.7 %) and piperacillin-
tazobactam (42.5 %) were the most common empiric β-
lactams prescribed (Table 2). Cloxacillin or cefazolin
(91.5 %) was the predominant empiric β-lactam used in
the monotherapy subgroup. Initiation of cloxacillin or
cefazolin was delayed in the combination subgroup com-
pared to the β-lactam monotherapy subgroup (median
Fig. 1 Patient enrollment process. Abbreviations: MSSA methicillin-susceptible S. aureus, BSI bloodstream infection
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Table 1 Baseline characteristics and clinical outcomes of patients with methicillin-susceptible S. aureus bacteremia. Patients received
empiric antimicrobial therapy with either β-lactams or vancomycin
Patient characteristics β-lactama (n=200) Vancomycina (n=200) P-value
Ageb 53.0 ± 16.9 57.9 ± 18.4 0.01
Males 126 (63.0) 132 (66.0) 0.53
Community-onset 173 (86.5) 158 (79.0) 0.05
Hospital-onset 27 (13.5) 42 (21.0) 0.05
HIV infection 20 (10.0) 16 (8.0) 0.48
Hepatitis C infection 61 (30.5) 55 (27.5) 0.51
Immunocompromised 18 (9.0) 16 (8.0) 0.72
Alcohol or illicit drug abuse 82 (41.0) 71 (35.5) 0.26
Intravenous drug use 64 (32.0) 56 (28.0) 0.38
Charlson comorbidity indexc 3 (1.0–6.0) 4 (1.0–7.0) 0.01
Pitt bacteremia scorec 1 (0–2) 1 (0–2) 0.18
Infectious diseases consultation 150 (75.0) 132 (66.0) 0.05
Source of bacteremia
Central or peripheral line 24 (12.0) 37 (18.5) 0.09
Skin and soft tissue 36 (18.0) 24 (12.0) 0.12
Intravenous drug use 48 (24.0) 39 (19.5) 0.33
Bone or joint infection 23 (11.5) 13 (6.5) 0.11
Lung 6 (3.0) 7 (3.5) 1.00
Other 19 (9.5) 20 (10.0) 1.00
Unknown 44 (22.0) 60 (30.0) 0.09
Infective endocarditis 45 (22.5) 23 (11.5) < 0.01
Metastatic complications 73 (36.5) 53 (26.5) 0.03
Surgical source control 43 (21.5) 26 (13.0) 0.02
Empiric antimicrobials
β-lactam 200 (100) 75 (37.5) < 0.0001
Cloxacillin or cefazolin 138 (69.0) 10 (5.0) < 0.0001
3rd generation cephalosporin 80 (40.0) 35 (17.5) < 0.0001
Piperacillin-tazobactam 69 (34.5) 35 (17.5) < 0.001
Ticarcillin-clavulanic acid 3 (1.5) 1 (0.5) 0.62
Carbapenem 8 (4.0) 4 (2.0) 0.24
Vancomycin 153 (76.5) 197 (98.5) < 0.0001
Daptomycin 2 (1.0) 1 (0.5) 1.00
Linezolid 2 (1.0) 2 (1.0) 1.00
Otherd 82 (41.0) 97 (48.5) 0.13
Blood culture time to positivitye 20.2 (16.6–25.5) 18.5 (16.2–23.3) 0.02
Duration of empiric therapye 55.4 (44.2–72.5) 52.1 (39.2–75.7) 0.55
Duration of definitive therapyf 28 (13.0–42.0) 26.5 (11.0–42.0) 0.14
Time to receipt of empiric therapye 1.92 (0.1–6.9) 10.8 (1.4–24.1) < 0.0001
Time to receipt of β-lactame 2.92 (0.3–13.8) 50.5 (4.8–75.5) < 0.0001
Time to receipt of cloxacillin or cefazoline 31.0 (13.8–50.8) 67.8 (50.3–88.0) < 0.0001
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34.8 vs 13.0 h, p=0.00). The combination subgroup had
a higher Pitt bacteremia score (median 1 vs 0, p < 0.01),
received more infectious diseases consultations (78.4 %
vs 63.8 %, p=0.05), and experienced more metastatic
complications (43.1 % vs 14.9 %, p < 0.001) than the β-
lactam monotherapy subgroup. Both the duration of
bacteremia (median 84.8 vs 63.4 h, p=0.03) and hospital
LOS (median 26 vs 15 days, p < 0.01) were longer in the
combination subgroup.
Almost half of patients in the vancomycin group re-
ceived additional antimicrobials during empiric or defini-
tive therapy (Table 1). Rifampin and aminoglycosides were
added for synergy in patients with prosthetic valve infect-
ive endocarditis or prosthetic joint infections. Fluoroqui-
nolones, macrolides, trimethoprim-sulfamethoxazole, and
clindamycin were used for either treatment of non-
bacteremic co-infections or prophylaxis for other med-
ical conditions. Three patients in the vancomycin group
received an incomplete dose of vancomycin and were
counted as not having received it.
There was a greater delay in receipt of empiric anti-
microbials in the vancomycin group compared to the
β-lactam group (median 10.8 vs 1.9 h, p < 0.0001)
(Table 1). Seventy five (37.5 %) patients in the vanco-
mycin group were briefly exposed to β-lactams during
empiric therapy. However, exposure time (median 0 vs
52.3 h, p < 0.0001) and proportional time of exposure of
the empiric period (median 0 vs 100 %, p < 0.0001) were
miniscule compared to the β-lactam group. There were
no differences in clinical outcomes between the two
groups (Table 3). The overall 28-day and 90-day mor-
tality was 34 (8.5 %) and 57 (14.3 %) respectively.
Among patients with infective endocarditis, 28-day and
90-day mortality was 4 (8.89 %) and 7 (15.6 %) in the β-
lactam group and 0 and 3 (13.0 %) in the vancomycin
group. In the vancomycin group, the subset of patients
who received brief exposure to empiric β-lactam expe-
rienced faster clearance of bacteremia compared to
those who did not have any empiric β-lactam exposure
(median 78.9 vs 96.3 h, p=0.04). In comparison with the
β-lactam group, patients in the vancomycin group who
did not have any empiric β-lactam exposure had slightly
higher 90-day mortality [22 (17.6 %) vs 25 (12.5 %), p=0.01]
and longer duration of bacteremia (median 96.3 vs 74.4 h,
p=0.03), while those who were briefly exposed to empiric
β-lactams exhibited no difference in clinical outcomes.
Discussion
The goal of our study was to assess if empiric β-lactams
compared to vancomycin was associated with differences
in outcomes in patients with MSSA bacteremia. We
found no differences in all-cause mortality at 28 and
90 days, recurrent infection at 6 months, duration of
bacteremia or hospital LOS between patients treated
with empiric β-lactam or vancomycin therapy. However,
in the vancomycin group, the subset of patients who
were not exposed to any empiric β-lactams had higher
90-day mortality and longer duration of bacteremia,
while those who had even minimal exposure to empiric
β-lactams did not have worse outcomes. Patients in the
vancomycin group were older, had more medical comor-
bidities, were less likely to be assessed by an infectious
diseases consultant, underwent fewer source control
procedures, and experienced a greater delay in receipt of
empiric antibiotics compared to the β-lactam group.
Table 1 Baseline characteristics and clinical outcomes of patients with methicillin-susceptible S. aureus bacteremia. Patients received
empiric antimicrobial therapy with either β-lactams or vancomycin (Continued)
Primary outcome
28-day mortality 16 (8.0) 18 (9.0) 0.72
Secondary outcomes
90-day mortality 25 (12.5) 32 (16.0) 0.32
Recurrent infection at 6 months 7 (3.5) 8 (4.0) 0.79
Duration of bacteremiae,j 74.4 (48.3–130) 89.7 (56.7–132) 0.20
≥ 3 daysj 98 (53.8) 111 (60.0) 0.25
Hospital length of stayf 22.5 (12.5–43.0) 22 (13.0–45.0) 0.59
aVariables are displayed as counts and percentages in parentheses unless otherwise specified
bAge is represented as a mean ± standard deviation in years
cVariables are expressed as a median with interquartile range in parentheses
dOther antimicrobials used during empiric and definitive therapy included rifampin, aminoglycosides, fluoroquinolones, macrolides, trimethoprim-sulfamethoxazole,
and clindamycin
eVariables are expressed as median hours with interquartile range in parentheses
fVariables are expressed as median days with interquartile range in parentheses
gVariables are expressed a mean ± standard deviation in hours
hVariables are expressed as median percentages with interquartile range in parentheses
iVariables are expressed a mean percentage ± standard deviation
jData missing for 18 and 15 patients in the β-lactam and vancomycin group, respectively
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Table 2 Baseline characteristics and clinical outcomes of patients with methicillin-susceptible S. aureus bacteremia. Patients received
either empiric combination therapy with β-lactam plus vancomycin or empiric β-lactam monotherapy
Patient characteristics β-lactam plus vancomycina (n=153) β-lactam monotherapya (n=47) P-value
Ageb 51.3 ± 16.9 58.7 ± 16.1 < 0.01
Males 92 (60.1) 34 (72.3) 0.17
Community-onset 137 (89.5) 36 (76.6) 0.03
Hospital-onset 16 (10.5) 11 (23.4) 0.03
HIV infection 18 (11.8) 2 (4.26) 0.17
Hepatitis C infection 50 (32.7) 11 (23.4) 0.28
Immunocompromised 12 (7.84) 6 (12.8) 0.38
Alcohol or illicit drug abuse 68 (44.4) 14 (29.8) 0.09
Intravenous drug use 54 (35.3) 10 (21.3) 0.08
Charlson comorbidity indexc 3 (1–6) 3 (1–5) 0.30
Pitt bacteremia scorec 1 (0–2) 0 (0–1) < 0.01
Infectious diseases consultation 120 (78.4) 30 (63.8) 0.05
Source of bacteremia
Central or peripheral line 15 (9.80) 9 (19.1) 0.12
Skin and soft tissue 25 (16.3) 11 (23.4) 0.28
Intravenous drug use 43 (28.1) 5 (10.6) 0.02
Bone or joint infection 15 (9.80) 8 (17.0) 0.19
Lung 4 (2.61) 2 (4.26) 0.63
Other 14 (9.15) 5 (10.6) 0.78
Unknown 37 (24.2) 7 (14.9) 0.23
Infective endocarditis 40 (26.1) 5 (10.6) 0.03
Metastatic complications 66 (43.1) 7 (14.9) < 0.001
Surgical source control 31 (20.3) 12 (25.5) 0.43
Empiric antimicrobials
Cloxacillin or cefazolin 95 (62.1) 43 (91.5) < 0.0001
3rd generation cephalosporin 73 (47.7) 7 (14.9) < 0.0001
Piperacillin-tazobactam 65 (42.5) 4 (8.51) < 0.0001
Ticarcillin-clavulanic acid 2 (1.31) 1 (2.13) 0.55
Carbapenem 7 (4.58) 1 (2.13) 0.68
Daptomycin 0 2 (4.26) 0.05
Linezolid 1 (0.65) 1 (2.13) 0.42
Otherd 60 (39.2) 22 (46.8) 1.00
Blood culture time to positivitye 20.3 (16.3–25.3) 19.8 (18.0–27) 0.36
Duration of empiric therapye 55.5 (44.9–73.8) 54.3 (38.8–64.5) 0.08
Duration of definitive therapyf 31 (14–43) 26 (12–40) 0.18
Time to receipt of empiric therapye 1.6 (0.03–6.17) 3.95 (0.58–15.5) 0.08
Time to receipt of β-lactame 2.77 (0.25–13.7) 3.95 (0.58–16.6) 0.74
Time to receipt of cloxacillin or cefazoline 34.8 (21.2–58.4) 13.0 (1.83–23.8) 0.00
Empiric β-lactam exposuree 52.3 (39.8–73.8) 51.7 (38.8–64.5) 0.42
Proportional empiric β-lactam exposureg 100 (86.1–100) 100 (95.2–100) 0.01
Primary outcome
28-day mortality 14 (9.15) 2 (4.26) 0.37
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More cases of infective endocarditis and metastatic com-
plications were diagnosed β-lactam group. Despite the
high prevalence of MRSA at both of our institutions
(25 % and 38 %), only 76.5 % of patients in the β-lactam
group received vancomycin empirically as well. Perhaps
the awareness of MRSA was low among some treating
clinicians or patients who did not receive empiric vanco-
mycin were judged to be at low risk for MRSA infection.
Although the combination of β-lactams with vanco-
mycin exhibits synergistic killing against MRSA, neither
synergy nor antagonism was observed against MSSA in
vitro [21]. Therefore, the addition of vancomycin to β-
lactams would not be expected to influence microbio-
logical cure in MSSA bacteremia.
Interestingly, the differential time delay in receipt of
empiric antimicrobials was unexpected. The β-lactam
group received antimicrobial therapy earlier possibly be-
cause these patients were more severely ill as reflected
in their higher rate of infective endocarditis and meta-
static complications, despite similar Pitt bacteremia
scores between the two groups. Infectious diseases con-
sultation may have also contributed to earlier initiation
of antibiotics in the β-lactam group.
In the β-lactam group, patients who received empiric
β-lactam plus vancomycin were generally sicker as indi-
cated by their higher Pitt bacteremia score, higher rate
of infective endocarditis and metastatic complications,
and longer duration of bacteremia and hospital LOS,
compared to those who received empiric β-lactam
monotherapy. The greater severity of illness in this
combination subgroup may explain the initial use of
broad-spectrum β-lactams (ceftriaxone or piperacillin-
tazobactam), with subsequent de-escalation to cloxacillin
or cefazolin in some patients during the empiric period by
the infectious diseases consultant when S. aureus was
identified in the blood culture. De-escalation occurred
within a median of 34.8 h, which follows the time to posi-
tivity of the first blood culture (median 20.3 h).
The 28-day and 90-day mortality in our study was low
at 34 (8.5 %) and 57 (14.3 %) respectively, but is within
the range of 3.6 to 51.7 % reported in a meta-analysis of
patients with MSSA bacteremia from catheter-related in-
fections and infective endocarditis by Cosgrove et al.
[22]. Definite infective endocarditis was diagnosed in 68
(17 %) of our patients, which is similar to rates reported
in previous studies [10, 14, 16, 23].
Table 2 Baseline characteristics and clinical outcomes of patients with methicillin-susceptible S. aureus bacteremia. Patients received
either empiric combination therapy with β-lactam plus vancomycin or empiric β-lactam monotherapy (Continued)
Secondary outcomes
90-day mortality 21 (13.7) 4 (8.51) 0.45
Recurrent infection at 6 months 5 (3.27) 2 (4.26) 0.67
Duration of bacteremiae,h 84.8 (52.5–136) 63.4 (30.5–114) 0.03
≥ 3 daysh 81 (56.3) 17 (44.7) 0.27
Hospital length of stayf 26 (13–45) 15 (10–30) < 0.01
aVariables are displayed as counts and percentages in parentheses unless otherwise specified
bAge is represented as a mean ± standard deviation in years
cVariables are expressed as a median with interquartile range in parentheses
dOther antimicrobials used during empiric and definitive therapy included rifampin, aminoglycosides, fluoroquinolones, macrolides, trimethoprim-sulfamethoxazole,
and clindamycin
eVariables are expressed as median hours with interquartile range in parentheses
fVariables are expressed as median days with interquartile range in parentheses
gVariables are expressed as median percentages with interquartile range in parentheses
hData missing for 9 patients in each subgroup
Table 3 Outcome analysis comparing β-lactam versus vancomycin group. Variables were adjusted for predefined confounding
variables, including age, sex, age-adjusted Charlson-comorbidity index, Pitt bacteremia score, infectious diseases consultation,
infective endocarditis and time to receipt of empiric antibiotics. Duration of bacteremia was further adjusted for surgical source control
Outcomes Crude OR (95 % CI) P-value Adjusted OR (95 % CI) P-value
28-day mortality 0.88 (0.44–1.78) 0.72 1.14 (0.49–2.64) 0.76
90-day mortality 0.75 (0.43–1.32) 0.32 1.01 (0.51–2.02) 0.97
Recurrent infection at 6 months 0.87 (0.31–2.45) 0.79 1.27 (0.39–4.11) 0.69
Ratio of Mean (95 % CI) P-value Adjusted Ratio of Mean (95 % CI) P-value
Duration of bacteremia 0.92 (0.78–1.07) 0.27 0.94 (0.79–1.11) 0.44
Hospital length-of-stay 0.96 (0.81–1.14) 0.65 0.95 (0.80–1.14) 0.60
Abbreviations: OR odds ratio, CI confidence interval
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In the vancomycin group, the median time to defini-
tive treatment with cloxacillin or cefazolin was 67.8 h,
which is comparable to other studies [3, 16, 17]. In the
Khatib study, a delayed clearance of bacteremia (≥ 3 days)
was observed in the vancomycin group compared to the
β-lactam group (57.6 % vs 37.5 %). However, there were
no differences in all-cause or attributable mortality be-
tween groups. Among injection drug users with predom-
inantly right-sided MSSA infective endocarditis, Lodise
et al. demonstrated that infection-related mortality was
lower with empiric β-lactam than with vancomycin
monotherapy (11.4 % vs 39.3 %, p=0.005) [17]. Even
when patients were switched from vancomycin to a
semi-synthetic penicillin within a median of 3 days,
infection-related mortality remained high at 40.9 %. The
overall mortality in this cohort was unusually high at
22.2 % compared to a rate of 0–4 % described in a sys-
tematic review by Yung et al. [24]. In contrast, a recent
study by McDanel et al. found that empiric β-lactam
therapy (predominantly piperacillin-tazobactam and cef-
triaxone) compared to vancomycin was not associated
with differences in mortality in patients with MSSA
bacteremia [15]. However, the McDanel study excluded
patients who received empiric vancomcyin plus β-
lactams, and clinical outcomes were evaluated independ-
ent of the antimicrobial prescribed for definitive therapy.
At institutions where MRSA prevalence is significant,
vancomycin is generally accepted as an appropriate em-
piric antimicrobial for SAB, but due to conflicting results
from prior studies, the addition of a β-lactam agent to
empiric therapy remains controversial. β-lactam mono-
therapy may be inadequate empiric treatment if the
strain is methicillin-resistant, but mortality outcomes
from retrospective studies are mixed [3, 6, 8, 25]. Ultim-
ately, the choice of empiric therapy will depend on pa-
tient factors, the prevalence of MRSA in the population,
and the ability of the microbiology laboratory to rapidly
differentiate MSSA from MRSA. From the perspective of
antimicrobial stewardship, vancomycin monotherapy
seems favourable as the reduction in usage of β-lactams
may decrease the potential for drug-drug interactions
and adverse effects during empiric therapy for SAB.
A particular strength of our study is the inclusion of
a large proportion of patients who received optimal
anti-MSSA agents (cloxacillin and cefazolin) empiric-
ally. The major limitation of previous studies was the
lack of transparency regarding the empiric β-lactams
prescribed [3, 17]. This is important because not all β-
lactams have the same activity against MSSA. In one
retrospective study, second and third generation cepha-
losporins and β-lactam/β-lactamase inhibitor combina-
tions were inferior to cloxacillin and cefazolin for
empiric treatment of MSSA bacteremia [26]. We did
not perform subgroup analysis for different β-lactams
because antimicrobials were frequently switched during
empiric therapy.
Our study has several limitations. The reason for the
lack of difference in the primary outcome is likely multi-
factorial. Because of the low event rate in both groups,
our study was potentially underpowered to detect a sig-
nificant difference in mortality. The lower than expected
death rate may be partly due to the exclusion of patients
who died within 24 h of the diagnosis of SAB and of pa-
tients who remained on broad-spectrum β-lactams. This
group may have represented a sicker population and
thus, we may have selected for less critically ill patients.
Due to the retrospective nature of this study, baseline
characteristics between the two groups were significantly
different, although we did attempt to control for these
differences in the multivariable model. Future studies
will need to employ matching strategies to eliminate this
imbalance. Although there appears to be a protective ef-
fect of even brief exposure to empiric β-lactams, caution
must be exercised when interpreting this data due to the
small sample size and major differences in baseline char-
acteristics between treatment groups. Because the source
of bacteremia was not identified in a significant propor-
tion of patients in both groups, clinical outcomes may
have been impacted by a lack of source control. As two
different microbiology laboratories were involved in the
study, differences in the detection methods of MSSA
may have affected the timing of definitive therapy.
Obtaining subsequent blood cultures was often delayed
or sometimes not performed at all, which may have led
to an overestimation of the duration of bacteremia in
both groups. Data regarding adverse effects were not
collected due to the inherent difficulty of establishing
drug-related events in a retrospective study. We were
not able to determine if patients received appropriate
dosing of antibiotics because data on antibiotic doses
and vancomycin trough levels were not collected. A ran-
domized controlled trial would be needed to confirm
our study findings.
Conclusions
Empiric therapy with β-lactams was not associated
with differences in all-cause mortality, recurrent infec-
tion, microbiological cure or hospital LOS compared
to vancomycin in patients with MSSA bacteremia.
Vancomycin monotherapy may be appropriate for the
empiric treatment of MSSA bacteremia if definitive
therapy with cloxacillin or cefazolin can be initiated
within 3 days.
Abbreviations
BSI: bloodstream infection; LOS: length-of-stay; MRSA: methicillin-resistant
Staphylococcus aureus; MSSA: methicillin-susceptible Staphylococcus aureus;
SAB: Staphylococcus aureus bacteremia.
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